2 publishers · first seen Tue, 10 Nov 2026 00:44 UTC · updated Wed, 11 Nov 2026 18:54 UTC
The US Food and Drug Administration (FDA) has mandated that all GLP-1 drugs include warning labels about the potential for sudden vision loss due to a rare condition called non-arteritic anterior ischemic optic neuropathy (NAION). This decision follows a study that found an association between semaglutide, the active ingredient in Ozempic and Wegovy, and vision loss. The FDA reviewed additional research and patient reports, but could not identify a mechanism for how GLP-1s may increase the risk of NAION. Despite this, the FDA is requiring the warning labels to be added to all GLP-1 drugs. The risk of NAION is considered low, with an estimated incidence of 6.4 cases per 100,000 patient-years among GLP-1 users. The FDA advises patients to seek immediate medical attention if they experience sudden, painless vision loss, blurred vision, or blind spots.
Content auto-generated. May contain inaccuracies.